GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nectar Lifesciences Ltd (LUX:NECLF) » Definitions » Price-to-Owner-Earnings

Nectar Lifesciences (LUX:NECLF) Price-to-Owner-Earnings : 7.52 (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Nectar Lifesciences Price-to-Owner-Earnings?

As of today (2024-06-10), Nectar Lifesciences's share price is $0.376. Nectar Lifesciences's Owner Earnings per Share (TTM) ended in Mar. 2024 was $0.05. It's Price-to-Owner-Earnings for today is 7.52.


The historical rank and industry rank for Nectar Lifesciences's Price-to-Owner-Earnings or its related term are showing as below:

LUX:NECLF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.11   Med: 5.5   Max: 9.57
Current: 7.12

During the past 13 years, the highest Price-to-Owner-Earnings of Nectar Lifesciences was 9.57. The lowest was 2.11. And the median was 5.50.


LUX:NECLF's Price-to-Owner-Earnings is ranked better than
90.61% of 426 companies
in the Drug Manufacturers industry
Industry Median: 25.375 vs LUX:NECLF: 7.12

As of today (2024-06-10), Nectar Lifesciences's share price is $0.376. Nectar Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, Nectar Lifesciences's PE Ratio for today is 125.33.

As of today (2024-06-10), Nectar Lifesciences's share price is $0.376. Nectar Lifesciences's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Nectar Lifesciences's PE Ratio without NRI for today is 125.33.

During the past 13 years, Nectar Lifesciences's highest PE Ratio without NRI was 383.33. The lowest was 4.33. And the median was 11.35.


Nectar Lifesciences Price-to-Owner-Earnings Historical Data

The historical data trend for Nectar Lifesciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nectar Lifesciences Price-to-Owner-Earnings Chart

Nectar Lifesciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.86 - - 4.85 7.24

Nectar Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.85 - - - 7.24

Competitive Comparison of Nectar Lifesciences's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nectar Lifesciences's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Nectar Lifesciences's Price-to-Owner-Earnings falls into.



Nectar Lifesciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Nectar Lifesciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.376/0.05
=7.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nectar Lifesciences  (LUX:NECLF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Nectar Lifesciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Nectar Lifesciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Nectar Lifesciences (LUX:NECLF) Business Description

Traded in Other Exchanges
Address
SCO 38-39, Sector 9d, B-1011/1012, 10th Floor NAURANG HOUSE, Chandigarh, IND, 160009
Nectar Lifesciences Ltd is an India-based pharmaceutical company. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products, The company's product includes cefixime trihydrate, cefdinir, cefprozil, cefoxitin sodium, cefpirome sulphate, and others. Geographically, it derives a majority of its revenue from India.

Nectar Lifesciences (LUX:NECLF) Headlines

No Headlines